![Tristan Brittain-Dissont](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Tristan Brittain-Dissont
Plus aucun poste en cours
Profil
Mr. Tristan Brittain-Dissont is Chief Executive Officer at Fusion Antibodies Ltd.
Mr. Brittain-Dissont was previously employed as a Fund Manager by E-Synergy Ltd., a Principal by SpringHill Management Ltd., Chief Executive Officer by Alpha Biologics Ltd., Chief Executive Officer by Psimei Pharmaceuticals Plc, and Non-Executive Director by Sphere Medical Ltd. He also served on the board at Bioventix Plc.
Anciens postes connus de Tristan Brittain-Dissont
| Sociétés | Poste | Fin |
|---|---|---|
E-Synergy Ltd.
 E-Synergy Ltd. Investment ManagersFinance E-Synergy invests in companies located in the UK and Northern Ireland. The firm targets technology companies, which is spin off from universities. They provides financing for seed and early stage capital requirements. | Analyste en capital-investissement | 31/10/2013 |
SpringHill Management Ltd.
 SpringHill Management Ltd. Investment ManagersFinance SpringHill is an active, value added manager which invests exclusively in life sciences companies at an early stage of their development or which are seeking development capital. The firm focuses on drug development, pharmaceutical services, medical devises, diagnostics, generics, super-generics and biogenerics sectors. The firm partners with their investee companies, aiming to add value by helping them develop their business plan or bring in key staff. Following investment, they provide mentoring to the investee businesses so they can focus on delivering milestones within budget and timeframe. In some cases, SpringHill assumes management roles and helps recruit experienced management teams and non-executive board members through their industry network. In addition, they drive corporate growth by providing external relationships to progress the investee businesses to commercialization and exit. SpringHill seeks to be the lead investor and plans for follow up investments from the start. They have experience bridging technologies, marketing, manufacturing capabilities and private equity between East and West and aim to provide such expertise to their investee companies. | Private Equity Investor | 31/12/2008 |
| BIOVENTIX PLC | Directeur/Membre du Conseil | 29/09/2008 |
| FUSION ANTIBODIES PLC | Directeur/Membre du Conseil | - |
Alpha Biologics Ltd.
 Alpha Biologics Ltd. Pharmaceuticals: MajorHealth Technology Manufactures biotechnology based pharmaceuticals | President | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
4
Relations au 1er degré
7
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Bioventix Plc
 Bioventix Plc BiotechnologyHealth Technology Develops and manufactures sheep monoclonal antibodies for use in the fields of clinical diagnostics and drugs of abuse testing | Health Technology |
SpringHill Management Ltd.
SpringHill Management Ltd. Investment ManagersFinance SpringHill is an active, value added manager which invests exclusively in life sciences companies at an early stage of their development or which are seeking development capital. The firm focuses on drug development, pharmaceutical services, medical devises, diagnostics, generics, super-generics and biogenerics sectors. The firm partners with their investee companies, aiming to add value by helping them develop their business plan or bring in key staff. Following investment, they provide mentoring to the investee businesses so they can focus on delivering milestones within budget and timeframe. In some cases, SpringHill assumes management roles and helps recruit experienced management teams and non-executive board members through their industry network. In addition, they drive corporate growth by providing external relationships to progress the investee businesses to commercialization and exit. SpringHill seeks to be the lead investor and plans for follow up investments from the start. They have experience bridging technologies, marketing, manufacturing capabilities and private equity between East and West and aim to provide such expertise to their investee companies. | Finance |
Sphere Medical Ltd.
 Sphere Medical Ltd. Electronic Equipment/InstrumentsElectronic Technology Develops monitoring and diagnostic products | Electronic Technology |
E-Synergy Ltd.
E-Synergy Ltd. Investment ManagersFinance E-Synergy invests in companies located in the UK and Northern Ireland. The firm targets technology companies, which is spin off from universities. They provides financing for seed and early stage capital requirements. | Finance |
Psimei Pharmaceuticals Ltd
 Psimei Pharmaceuticals Ltd Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Alpha Biologics Ltd.
Alpha Biologics Ltd. Pharmaceuticals: MajorHealth Technology Manufactures biotechnology based pharmaceuticals | Health Technology |
Fusion Antibodies Plc
 Fusion Antibodies Plc Medical/Nursing ServicesHealth Services Develops antibody-based therapeutic products | Health Services |
